1 to 4 of 4 |
The Centers for Medicare & Medicaid Services (CMS) decision not to reimburse everyday Americans for using what the FDA determined to be an effective diagnostic tool was found to be “arbitrary and capricious” by a Federal court. The reason? Because Medicare is reimbursing for a less effective diagnostic tool and did not explain why it would not do so for a more innovative tool.
Sen. Susan Collins (R-ME), chairman of the Senate Aging Committee, is prodding her Senate colleagues for approval of an additional $414 million in FY 2018 funding she says is needed by the National Institutes of Health (NIH) in order to meet the goal of preventing or effectively treating Alzheimer&r...
As the Alzheimer’s Association International Conference (AAIC) kicks off Friday, July 22, in Toronto, UsAgainstAlzheimer’s (UsA2) is poised to be a major participant across a number of fronts, including research, clinical trial recruitment, minimizing disparities, and improving caregiver support. The organization will add its voice to those of international investigators, clinicians and care providers in an effort to advance science and see critical dementia breakthroughs come to fruition.
Western New Yorkers with Alzheimer’s disease and other dementias will soon have access to improved care, thanks to a five-year, $2.35 million New York State grant to researchers in the Jacobs School of Medicine and Biomedical Sciences at New York State University at Buffalo.
Sens. Susan Collins (R-ME), chair of the Senate Special Committee on Aging, and Amy Klobuchar (D-MN), ranking member on the Senate Joint Economic Committee, late last week took the lead in crafting a bipartisan letter calling on President Barack Obama to increase federal funding for Alzheimer’s research as part of his fiscal year (FY) 2017 budget request.
Alzheimer’s disease represents a personal health crisis, but it’s also a family concern. When someone is diagnosed with Alzheimer's, what does that mean in terms of the risk his or her children and siblings might face?
The study's results, which required over a year's worth of intensive data collection and analysis, could hold important insights for drug companies. That's because selecting less relevant data early in the research process can create costly errors later in the "translational pipeline" that connects basic science to new treatments and therapies.
1 to 4 of 4 |